Dublin firm Jazz may be next takeover target for drugmakers

JAZZ Pharmaceut-icals just got more alluring as a takeover target after adding to its suite of medicines for rare diseases.

With drugmakers on the prowl for targets in Ireland because of the lower corporate tax rate, investors have been speculating that Dublin-based Jazz may be among the next companies to draw bids.

Jazz’s enviable tax base is only part of the appeal as the $7.3bn (€5.34bn) firm bolsters its product lineup with the $1bn purchase of rare-disease drug developer Gentium.